This article is about pharmaceutical companies having to submit applications for their treatments
to be labeled as "orphan drugs" (a drug used to treat any disease with
less than 200,000 affected in the US). With this designation,
companies receive several incentives, including tax breaks and
marketing privileges, that help to offset the fact that they have a
very limited pool of people to which they can sell their product. My
mom works for one of the companies mentioned in this article, and she
has had the opportunity to work on a drug called Sabril, used to treat
a type of seizure affecting about 8,500 infants. I know that this drug
has been a huge endeavor for the company and there has been several
obstacles, including finding enough subjects to use for clinical
support of the drug's effectiveness. I think that this is interesting
to us as future physicians for several reasons and serves as a
reminder that there are many interactions involved in medicine in
addition to the one occurring between the doctor and the patient.
http://online.wsj.com/article/



